TITLE

Moving Up

PUB. DATE
June 2009
SOURCE
Pharmaceutical Representative;Jun2009, Vol. 39 Issue 6, p32
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article announces the promotions of Greg Gwisc and Khari Mitchell promoted to Professional Pharmaceutical Sales Representative (PPSR) at Endo Pharmaceuticals Inc.
ACCESSION #
40521983

 

Related Articles

  • NEWSLINE: Crush-resistant Opana ER.  // Monthly Prescribing Reference;Jan2012, Vol. 28 Issue 1, pA-7 

    The article reports that the crush resistant formulation of Opana ER extended-release tablets from Endo Pharmaceuticals Inc. has been approved.

  • FORTESTA.  // MPR - Urologists' Edition;Spring/Summer2011, Vol. 8 Issue 1, pA8 

    The article offers information on Fortesta gel formulation from Endo Pharmaceuticals Inc.

  • New Dosages.  // Drug Topics;1/17/2000, Vol. 144 Issue 2, p82 

    Presents information on the additional strengths of the pain-relief medication Percocet CII manufactured by Endo Pharmaceuticals Incorporated. Formulation of original Percocet.

  • FORTESTA.  // Monthly Prescribing Reference;May2011, Vol. 27 Issue 5, pA.6 

    The article offers brief information on the Fortesta testosterone gel for treatment of hypogonadism from Endo Pharmaceuticals Inc.

  • Valrubicin Is Reintroduced for the Treatment of CIS.  // Renal & Urology News;Oct2009, Vol. 8 Issue 10, p24 

    The article evaluates Valstar (valrubicin) from Endo Pharmaceuticals Inc.

  • Crush-Resistant Opana ER.  // Monthly Prescribing Reference;Jul2012, Vol. 28 Issue 7, pA6 

    The article reports that Endo Pharmaceuticals Inc. has changed its Opana ER drugs to a Class II opioid narcotic as previous one can be subjected to misuse and inadvertent abuse.

  • Endo's chronic low back pain study fails to meet predetermined end points.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p15 

    The article reports on the negative results obtained by Endo Pharmaceuticals Inc. from a phase II study that compares the novel investigational drug axomadol against placebo in the treatment of patients with moderate to severe chronic low back pain.

  • Crush-resistant Opana ER.  // Monthly Prescribing Reference;Jan2013, Vol. 29 Issue 1, pA15 

    The article offers information on the launch of a crush resistant Opana Extended Release (ER) tablet from Endo Pharmaceuticals Inc.

  • Ohio to receive $5M+ in Endo Pharmaceuticals Case.  // Toledo Business Journal;Apr2014, Vol. 30 Issue 4, p18 

    The article reports that according to Ohio Attorney General Mike DeWine, Ohio will receive more than 5 million dollars in global settlement with pharmaceutical firm Endo Pharmaceuticals Inc. which was accused of being involved in unlawful marketing practices for promoting the drug Lidoderm.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics